Login to Your Account

Edesa lands $7M series A to advance contact dermatitis drug through phase IIb

By Michael Fitzhugh
Staff Writer

Wednesday, September 20, 2017

Edesa Biotech Inc., a Canadian startup developing dermatology and anorectal therapies, has raised a $7 million series A financing to fund a phase IIb trial of EB-01, a topical secretory phospholipase A2 inhibitor therapy it is developing for the treatment of allergic contact dermatitis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription